Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

NIH

Sponsor class

Conditions

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma
Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Refractory Grade 1 Follicular Lymphoma
Refractory Grade 2 Follicular Lymphoma
Refractory Grade 3a Follicular Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Stage IB Mycosis Fungoides AJCC v7
Stage II Mycosis Fungoides AJCC v7
Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage III Mycosis Fungoides AJCC v7
Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
Stage IV Mycosis Fungoides AJCC v7

Interventions

BIOLOGICAL: Anti-ICOS Monoclonal Antibody MEDI-570
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)